Stryker Bid for Smith & Nephew Has 80% Chance of Success: Exane
2014-06-25 10:14:25.768 GMT
By Allison Connolly
June 25 (Bloomberg) -- Exane see clear strategic rationale
for merger while co. turnaround strategy remains valid,
according to note.
* Ests. Smith & Nephew organic growth of at least 4% from 2015
onwards vs current 2%-3%; cites focus on M&A, EMs for growth
* Raises PT to 1,250p vs 1,000p (outperform)
* NOTE: May 29, Stryker Denies Report It’s Planning Smith &
Nephew Bid
* NOTE: June 5, Stryker Retains Right to Smith & Nephew Bid If
Medtronic Bids
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editors responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net
Jurjen van de Pol
2014-06-25 10:14:25.768 GMT
By Allison Connolly
June 25 (Bloomberg) -- Exane see clear strategic rationale
for merger while co. turnaround strategy remains valid,
according to note.
* Ests. Smith & Nephew organic growth of at least 4% from 2015
onwards vs current 2%-3%; cites focus on M&A, EMs for growth
* Raises PT to 1,250p vs 1,000p (outperform)
* NOTE: May 29, Stryker Denies Report It’s Planning Smith &
Nephew Bid
* NOTE: June 5, Stryker Retains Right to Smith & Nephew Bid If
Medtronic Bids
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editors responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net
Jurjen van de Pol